Quantcast

Exelixis and BMS to evaluate cancer drug combination

Exelixis and Bristol-Myers Squibb have entered into a clinical development collaboration to evaluate Cabometyx (cabozantinib), Exelixis’ small molecule inhibitor of receptor tyrosine kinases, with Opdivo (nivolumab), Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor, either alone or in combination with Yervoy (ipilimumab).

Read more

Ipsen’s and Exelixis’ Cabozantinib lowers disease progression and death rate by 31%

Ipsen and its partner Exelixis today announced detailed results from the CABOSUN randomized phase 2 trial of cabozantinib in patients with previously untreated advanced renal cell carcinoma (RCC) with intermediate- or poor-risk disease per the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).

Read more